Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing data from...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines Vol. 11; no. 9; p. 2424
Main Authors: Bagnasco, Diego, Nicola, Stefania, Testino, Elisa, Brussino, Luisa, Pini, Laura, Caminati, Marco, Piccardo, Federica, Canevari, Rikki Frank, Melissari, Laura, Ioppi, Alessandro, Guastini, Luca, Lombardi, Carlo, Milanese, Manlio, Losa, Francesca, Robbiano, Michela, De Ferrari, Laura, Riccio, Anna Maria, Guida, Giuseppe, Bonavia, Marco, Fini, Donatella, Balbi, Francesco, Caruso, Cristiano, Paggiaro, Pierluigi, Blasi, Francesco, Heffler, Enrico, Paoletti, Giovanni, Canonica, Giorgio Walter, Senna, Gianenrico, Passalacqua, Giovanni
Format: Journal Article
Language:English
Published: Basel MDPI AG 30-08-2023
MDPI
Subjects:
Asthma
Biological products
Clinical trials
CRSwNP
Cytokines
Disease
Drug dosages
eosinophils
IL-5
Inflammation
Medical research
Medicine, Experimental
mepolizumab
Nitric oxide
Polyps
real life
severe asthma
Steroids
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing data from SANI (Severe Asthma Network Italy) clinics, we observed severe asthmatic patients treated with mepolizumab 100 mg/4 weeks, for a period of 3 years. 157 patients were observed. Exacerbations were reduced from the first year (−84.6%) and progressively to 90 and 95% in the second and third ones. Steroid-dependent patients decreased from 54% to 21% and subsequently to 11% in the second year and 6% in the third year. Patients with concomitant nasal polyps, assessed by SNOT-22, showed a 49% reduction in value from baseline to the third year. The study demonstrated the long-term efficacy of mepolizumab in a real-life setting.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Membership of SANI is provided in Appendix A.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines11092424